{"ModuleTitle": "Company Description", "CompanyName": "Oramed Pharmaceuticals Inc.", "Symbol": "ORMP", "Address": "1185 AVENUE OF THE AMERICAS, SUITE 228, NEW YORK, New York, 10036, United States of America", "Phone": "646-844-1164", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "Middle East", "CompanyDescription": "We are a pharmaceutical company currently engaged in the research and\r\ndevelopment of innovative pharmaceutical solutions, including an oral insulin\r\ncapsule to be used for the treatment of individuals with diabetes, and the use\r\nof orally ingestible capsules or pills for delivery of other polypeptides. We\r\nutilize Clinical Research Organizations, or CROs, to conduct our clinical\r\nstudies.\r\n\r\n \r\n\r\nOral insulin: We are seeking to transform the treatment of diabetes through our\r\nproprietary flagship product, an orally ingestible insulin capsule, or\r\nORMD-0801. Our technology allows insulin to travel from the gastrointestinal\r\ntract via the portal vein to the bloodstream, revolutionizing the manner in\r\nwhich insulin is delivered. It enables the passage in a more physiological\r\nmanner than current delivery methods of insulin. Our technology is a platform\r\nthat has the potential to deliver medications and vaccines orally that today can\r\nonly be delivered via injection.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2019%2f11%2f27%2f0001213900-19-024940.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Avraham Gabay", "title": "Chief Financial Officer, Secretary & Treasurer"}, {"name": "Joshua Hexter", "title": "Chief Operating & Business Officer"}, {"name": "Miriam Kidron", "title": "Director & Chief Scientific Officer"}, {"name": "Nadav Kidron", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}